Head-To-Head Analysis: BioLargo (BLGO) vs. The Competition

BioLargo (NASDAQ:BLGOGet Free Report) is one of 34 publicly-traded companies in the “Chemicals & allied products” industry, but how does it contrast to its competitors? We will compare BioLargo to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, institutional ownership and profitability.

Insider & Institutional Ownership

0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

BioLargo has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, BioLargo’s competitors have a beta of 1.78, indicating that their average share price is 78% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for BioLargo and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLargo 0 0 0 0 N/A
BioLargo Competitors 139 1276 1593 46 2.51

As a group, “Chemicals & allied products” companies have a potential upside of 7.20%. Given BioLargo’s competitors higher possible upside, analysts clearly believe BioLargo has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares BioLargo and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioLargo $12.23 million -$3.50 million -8.00
BioLargo Competitors $6.64 billion $206.77 million 66.99

BioLargo’s competitors have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares BioLargo and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLargo -16.53% -58.35% -32.12%
BioLargo Competitors -568.74% 5.73% -0.15%

Summary

BioLargo competitors beat BioLargo on 8 of the 10 factors compared.

BioLargo Company Profile

(Get Free Report)

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.